Jonathan Coulter

    Jonathan Coulter

    Senior Lecturer

    Phone: +44 (0)28 9097 2253

    For media contact email
    or call +44(0)2890 973091.

    View graph of relations



    Functionalised gold nanoparticles

    Targeting strategies

    Gene Therapy

    Nitric Oxide

    Prostate Cancer


    Tumour inflammation

    Research Statement

    Dr Jonathan Coulter obtained his PhD within the School of Pharmacy at Queens University Belfast in 2006. His project focused on tumour specific, transcriptionally targeted gene therapy strategies focused on over expressing inducible nitric oxide synthase with an aim to sensitise tumour cells to ionising radiation.

    In October 2006, appointed as a research fellow he joined the multidisciplinary gold nanoparticle (AuNP) research group. This research aims to exploit the physical properties of gold (i.e. the high atomic number and the differential absorption coefficient between high Z materials and soft tissue) to sensitise cells to radiation treatment. He is specifically interest in the biological factors that influence the efficacy of these experimental therapies. 

    Appointed as a Lecturer within the School of Pharmacy in June 2012, his research group has developed a functionalised-GNP capable of doubling the cell killing efficacy ionising radiation, with minimal cytotoxic effects when used as solo agents. In a separate strategy Dr Coulter is also investigating role of hypoxia in maintaining cancer stem cell populations, know to exhibit significant resistance to conventional therapeutics, including radiotherapy. 

    Jonathan has published twenty scientific publications, written and edited a book, and has given numerous conference presentations. He was a visiting scientist at the University Hospital Network (UHN) in Toronto, working in Prof. Rob Bristow’s laboratories. He has received funding from Prostate Cancer UK, Breast Cancer Campaign and Cancer Research UK. He is a committee member on the Irish Radiation Research Society and the Association for Radiation Research, and an editorial board member of Cancer Nanotechnology, NanoDrugs and Clinical and Experimental Pharmacology. 


    Contributes to the following modules on the MPharm degree:

    • PMY1014 Introduction to Pharmacy Practice Skills
    • PMY2104 Pharmacological Basis of Therapeutics
    • PMY2105 Clinical Therapeutic 1 
    • PMY3175 Clinical Therapeutics 3
    • PMY3072 Pharmaceutical Biotechnology 
    • PMY4073 Infectious Diseases
    • PMY4005 Level 4 Project


    Distance Learning Supervisor:

    • PG Diploma in Clinical Pharmacy
    • MSc Clinical Pharmacy

    Willingness to take PhD students


    PhD projects

    Open to PhD applications in the field of Nanotherapeutics, radiobiology, radiopharmaceuticals, DNA damage, cancer stem cells, drug resistance, 3-dimentional bio-assays.
    - Gold nanoparticle/drug combinations
    - Solid tumour nanoparticle transport models

    Frequent Journals

    • Nature Scientific Reports

      ISSNs: 2045-2322

      Additional searchable ISSN (Electronic): 2045-2322

      Nature Publishing Group

      Scopus rating (2018): CiteScore 4.29 SJR 1.414 SNIP 1.24


    • Cancer Nanotechnology

      ISSNs: 1868-6958

      Springer Science + Business Media

      Scopus rating (2018): CiteScore 5 SJR 1.22 SNIP 1.106


    • The Journal of Gene Medicine

      ISSNs: 1099-498X

      Additional searchable ISSN (Electronic): 1521-2254

      John Wiley and Sons Ltd

      Scopus rating (2018): CiteScore 1.49 SJR 0.48 SNIP 0.448


    • Nanomedicine

      ISSNs: 1743-5889

      Future Medicine Ltd.

      Scopus rating (2018): CiteScore 3.84 SJR 1.069 SNIP 0.841


    • Radiotherapy and Oncology

      ISSNs: 0167-8140

      Additional searchable ISSN (Electronic): 1879-0887


      Scopus rating (2018): SJR 2.023 SNIP 1.562


    View all »

    View all

    Contribution to conference papers, events and activities

    ID: 44686